XUANZHUBIO-B

Xuanzhu Biopharmaceutical-B (2575.HK) opened higher and rallied in the morning session, reaching HKD 12.200 as of 09:32 BJT, up 7.68%, driven by NMPA NDA acceptance for anaprazole sodium in reflux esophagitis and first patient enrollment in its Phase III H. pylori eradication trial. The intraday low was HKD 11.610 and high HKD 12.200, with a range of ~5.1%. Q4 2025 operating revenue surged 151.8% YoY to HKD 18.84 million, while net loss narrowed 68.42% YoY to HKD 74.84 million, showing continued improvement. The stock remains 87.41% below its 52-week high of HKD 96.9, but has reclaimed the MA20 (HKD 11.973) and is 15.09% above the 52-week low of HKD 10.6, indicating a low base and short-term recovery. However, the company faces a RMB 9.33 million CIETAC arbitration award, and its PE of -23.27 reflects ongoing losses.

Xuanzhu Biopharma traded weak in the morning session, opening at HKD 12.30 and sliding to close at HKD 11.66, down 5.2%, with turnover of only HKD 1.29 million. The stock hit a fresh 52-week low of HKD 11.66 during the session. The decline was primarily driven by a recent CIETAC arbitration ruling ordering the company to pay RMB 9.33 million. Shares have plunged 88% from their 52-week high of HKD 96.9 and are down 82.1% YTD. Despite Q4 2025 revenue surging 151.8% YoY to HKD 18.8 million and net loss narrowing 68.4% YoY, the net profit margin remained deeply negative at -397% and PB stood at 3.98x. The stock also traded below both its 20-day MA (HKD 11.98) and 60-day MA (HKD 13.96), signaling weak price momentum. However, the NMPA's acceptance of a new drug application for anaprazole sodium in reflux esophagitis and the Phase III trial for H. pylori eradication may provide some support.

Xuanzhu Biopharma-B (2575.HK) opened higher and rallied intraday, reaching a session high of HK$13.31, up about 6.6% from yesterday's close of HK$12.48, before pulling back to HK$12.83, with gains narrowing to 2.8%. The move was driven by recent regulatory progress: the company announced NMPA acceptance of the NDA for anaprazole sodium in reflux esophagitis and initiation of first patient enrollment in a Phase III trial for H. pylori eradication. However, fundamental pressures persist: Q4 2025 revenue was HK$18.84 million, up 151.8% YoY, while net loss was HK$74.84 million, narrowing 68.42% YoY, with EPS of -HK$0.1562. At HK$12.83, the stock trades below its 60-day MA of HK$14.69, with YTD decline of 80.32% and 86.76% off its 52-week high of HK$96.9, reflecting ongoing valuation headwinds from sustained losses. Though, a recent CIETAC arbitration award ordering payment of RMB 9.33 million introduces legal overhang.

Xuanzhu Biopharma-B staged a sharp intraday reversal this morning, opening low at HK$11.80 before surging to close at HK$12.49, up 5.85% on the day. The rally was driven by the NMPA's acceptance of the NDA for anaprazole sodium in reflux esophagitis, following the drug's Phase III enrollment for H. pylori eradication. Total turnover was a thin HK$1.85 million. Q4 revenue jumped 152% YoY to HK$18.8 million, with net loss narrowing 68% to HK$74.8 million, though EPS remained negative at -HK$0.1562. The stock has plunged 87% from its 52-week high of HK$96.9, with a YTD decline of 81%, and sits just 18% above the 52-week low of HK$10.6, still below the MA60 (HK$15.15) and barely above the MA20 (HK$12.10). However, the pending RMB 9.33 million arbitration award payout remains a latent overhang.

Xuanzhu Biopharma opened lower in the morning session but rallied sharply, gaining 5.0% from its open of HK$11.58 to hit HK$12.16. The move was driven by a series of recent regulatory and clinical catalysts: the NMPA accepted a new NDA for anaprazole sodium in reflux esophagitis, the first patient was enrolled in its Phase III trial for H. pylori eradication, and strong Phase III lung cancer data for its ALK inhibitor diroalkib were reported. Q4 revenue surged 151.8% YoY to HK$18.8 million, while net loss narrowed 68.42% YoY. However, at HK$12.16, the stock remains 87.45% below its 52-week high of HK$96.90 and 81.35% down year-to-date, trading below the MA60 of HK$15.30. The PB stands at 4.15x, though turnover of just HK$2.2 million suggests limited liquidity.